mAbs · 2021
A human antibody of potent efficacy against SARS-CoV-2 in rhesus macaques showed strong blocking activity to B.1.351.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Gu Chunyin, Cao Xiaodan, Wang Zongda, Hu Xue, Yao Yanfeng, Zhou Yiwu, Liu Peipei, Liu Xiaowu, Gao Ge, Hu Xiao, Zhang Yecheng, Chen Zhen, Gao Li, Peng Yun, Jia Fangfang, Shan Chao, Yu Li, Liu Kunpeng, Li Nan, Guo Weiwei, Jiang Guoping, Min Juan, Zhang Jianjian, Yang Lu, Shi Meng, Hou Tianquan, Li Yanan, Liang Weichen, Lu Guoqiao, Yang Congyi, Wang Yuting, Xia Kaiwen, Xiao Zheng, Xue Jianhua, Huang Xueyi, Chen Xin, Ma Haixia, Song Donglin, Pan Zhongzong, Wang Xueping, Guo Haibing, Liang Hong, Yuan Zhiming, Guan Wuxiang, Deng Su-Jun
Аннотация
Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), which causes coronavirus disease-2019 (COVID-19), interacts with the host cell receptor angiotensin-converting enzyme 2 (hACE2) via its spike 1 protein during infection. After the virus sequence was published, we identified two potent antibodies against the SARS-CoV-2 receptor binding domain (RBD) from antibody libraries using a phage-to-yeast (PtY) display platform in only 10 days. Our lead antibody JMB2002, now in a Phase 1 clinical trial (ChiCTR2100042150), showed broad-spectrum in vitro blocking activity against hACE2 binding to the RBD of multiple SARS-CoV-2 variants, including B.1.351 that was reportedly much more resistant to neutralization by convalescent plasma, vaccine sera and some clinical-stage neutralizing antibodies. Furthermore, JMB2002 has demonstrated complete prophylactic and potent therapeutic efficacy in a rhesus macaque disease model. Prophylactic and therapeutic countermeasure intervention of SARS-CoV-2 using JMB2002 would likely slow down the transmission of currently emerged SARS-CoV-2 variants and result in more efficient control of the COVID-19 pandemic.